Skip to content

Study and application of the introduced traditional medicine Maca belonging to the kidney meridian medicinal property and  tonifying the kidney and essence effect

Study and application of the introduced traditional medicine Maca belonging to the kidney meridian medicinal property and  tonifying the kidney and essence effect

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086680
Enrollment
Unknown
Registered
2024-07-09
Start date
2024-07-15
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aging

Interventions

Experimental group:Take Guozhen brand maca tablet candy

Sponsors

Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 75 Years

Inclusion criteria

Inclusion criteria: Meet all of the following conditions: (1) Fried fassy Phenotype Scale score 1-2 points; (2) Meet the diagnostic criteria of TCM kidney essence deficiency syndrome"Scoring Table for Traditional Chinese Medicine Syndrome of Kidney Essence Deficiency Syndrome"; (3) Age =55 years old and =75 years old, male or female; (4) Voluntarily participate in this study and sign a written informed consent.

Exclusion criteria

Exclusion criteria: Any of the following: (1) suffering from serious primary diseases of the heart, lung, liver, kidney, hematopoietic and nervous system and/or unstable disease status; (2) suffering from serious mental illness or cognitive impairment; (3) In line with the diagnostic criteria of traditional Chinese medicine heat syndrome or normal easy fire constitution, heat syndrome: fever, aversion to heat and cold, thirst to drink, red face, irritability, thick phlegm, short yellow urine, dry stool, red tongue and less fluid, yellow and dry fur, pulse number, etc. (4) Patients with a history of alcohol or drug abuse within 1 year prior to enrollment; (5) Participants who participated in other drug clinical trials within 1 month before screening; (6) Known or suspected to have a history of allergy or allergy to the experimental drug and its excipients; (7) Patients deemed unsuitable for study participation by the investigator due to possible violations of the trial protocol or any other circumstances affecting its safety.

Design outcomes

Primary

MeasureTime frame
Tilburg frailty Assessment Scale;Traditional Cinese Medicine syndrome evaluation table;

Secondary

MeasureTime frame
Grip strength;pace;Quality of Life Assessment Scale (SF-36);Superoxide dismutase,SOD;Malondialdehyde,MDA;Glutathione peroxidase,GSH-Px;routine blood test;

Countries

China

Contacts

Public ContactLinyuan Wang

Beijing University of Chinese Medicine

wangly@bucm.edu.cn+86 133 8100 2202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026